S-1 · resale registration
Issued 2026
Proposed maximum
Shares registered
- Filed
- Effective
JUNS$2.47+6.93%
Jupiter Neurosciences, Inc.
Sector: Pharmaceutical PreparationsIndustry: BiotechnologyCountry: USExchange: Nasdaq
Mkt Cap:$3.26M
Float & O/S:
Inst Own:
DilutionScan read 38 of JUPITER NEUROSCIENCES, INC.'s SEC filings and found 2 warrant series, 3 convertibles, 1 equity line, 2 shelf registrations, 2 S-1 registrations and 7 completed offerings on file for JUNS. The latest dilution event on file is a registration statement on Sep 25, 2026. Analysis updated Oct 3, 2026.
Signal8 Summary
JUNS
Going-concern warning; zero cash runway
Snapshot
Jupiter Neurosciences is a clinical-stage biotech with essentially no revenue ($22K in FY 2025) and massive losses ($8.6M net loss). The company burns cash quickly ($5.4M in free cash flow annually) and holds only $3.8M in cash against $5.3M in debt, resulting in a cash runway of less than one month.
What's Happening Right Now
- : Jupiter signed a definitive agreement for exclusive U.S. rights to ALA-002, a next-generation MDMA therapeutic, in a transaction valued up to $100 million.
- : The company is seeking stockholder approval for a reverse stock split between 1-for-10 and 1-for-100 to regain compliance with Nasdaq listing rules.
- : Jupiter closed a $2.0 million registered direct offering, issuing over 7 million shares to extend cash runway and pay down debt.
Raise routes on file: effective shelf + effective S-1 + active equity line · latest dilution event 39 days ago
Overall Risk
Offering Ability
Overhead Supply
Historical
Cash Need
AI dilution summary
The dominant contractual driver and its mechanism, then each further driver ranked.
Latest dilution event
Sep 25, 2026 · Registration
Every warrant, convertible, ATM and shelf, cited to the filing
A free account reads 3 tickers a day in full
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
Share count and cash history
Shares outstanding, potential dilution and cash over time
Effective
S-1 · resale registration
Issued 2025
Proposed maximum
Shares registered
- Filed
- Effective
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Warrant
Shares Underlying
Exercise Price
Outstanding
- Type
- Anti-Dilution
- Cashless Exercise
- Expiration
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Convertible
Principal
Conversion Price
Remaining principal
- Shares on conversion
- Interest rate
- Maturity
Equity line
Issued 2025
Commitment
Sold to date
Remaining
- Agreement date
- Term ends
- Discount
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
S-3 shelf registration
Issued 2026
Total capacity
Remaining
- Filed
- Effective
- Expires
- Baby shelf
Registered direct offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Registered direct offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Offering
Issued 2026
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
PIPE
Issued 2025
Gross proceeds
Price per share
- Shares issued
- Warrant coverage
- Placement agent
Know who's about to sell into your JUNS trade
Exercise prices, conversion terms, shelf headroom and the filing sentence behind every number.
$59/mo with 7 days free, or $49/mo billed yearly ($588/yr)
